Jia Luo, MD
LightNews LightNews
banner
jia-luo.bsky.social
Jia Luo, MD
@jia-luo.bsky.social
1.2K followers 150 following 110 posts
Thoracic medical oncologist and cancer researcher at Dana-Farber/ Harvard Cancer Center
// Prev MSKCC Fellow, OHSU IM & Chief Res, Stanford Med, and UW-Madison
https://t.co/Y9HwVQ1jyq
Posts Replies Media Videos
jia-luo.bsky.social
What a great throwback!

Brings me back to middle school computer lab when - as the cool kids - we were using this little known search called "google" on our bright boxy blue iMacs when the standard at the time was Ask Jeeves
September 27, 2025 at 5:29 PM
jia-luo.bsky.social
What a fantastic IASLC WCLC25!

Congrats to star resident (onc-to-be!) Dr Huang &

We had a superb global multi-D discussion on ground glass/semisolid lung nodules - packed room in our last session of the day!

TY chairs Drs Naidoo Opitz Malapelle & Noemi - feeling inspired 🙏
@iaslc.bsky.social
September 10, 2025 at 3:40 AM
jia-luo.bsky.social
🩻 Look forward to our interactive multidisciplinary lung nodules session @ IASLC WCLC 2025 meeting next week, September 6-9 in Barcelona

It's been fantastic to plan our program with this group of experts spanning the 🗺️, meeting 6am (PT) - 11pm (AEST)!
wclc.iaslc.org #lcsm @iaslc.bsky.social #WCLC25
August 29, 2025 at 6:36 PM
jia-luo.bsky.social
Fantastic to interview Dr. William Pao about his book "Breakthrough" with Dr. Jänne

So inspiring for us to hear stories about resiliency and learning from failure in research to develop transformational medicines

Special thanks to Sitara & the Chen-Huang Center #lcsm @danafarber.bsky.social
Photos of the Endowed Lecture interview with Dr Wiliam Pao, including Drs Luo, Jänne, Rotow, Barbie, Sitara and the in person crowd
August 12, 2025 at 7:58 PM
jia-luo.bsky.social
Excited to host drug developer extraordinaire Dr. William Pao at Dana-Farber

Dr. Jänne and I will interview Dr. Pao tomorrow (Tuesday, August 12) about his book, Breakthrough, "a triumphant read about overcoming disease"

www.simonandschuster.com/books/Breakt... @danafarbernews.bsky.social
August 11, 2025 at 2:44 PM
jia-luo.bsky.social
Celebrating endings and new beginnings - it has been fantastic to have Dr Paoloni on our research team during his awarded American-Italian Cancer Foundation Research Fellowship grant!

@danafarber.bsky.social @danafarbernews.bsky.social #lcsm
Research group dinner. From left to right: Dr Paoloni, Huang, Sara Walton, Justin Kim, Dr Luo, and Dr Pecci Dr Paoloni (center) with Drs French and Luo
August 4, 2025 at 2:08 PM
jia-luo.bsky.social
End/ Thank you to 💫 first author @justinjkim.bsky.social, Prof French, co-author experts and collaborators, our patients, and funding sources, including NIH NCI

Accompanying article: www.dana-farber.org/newsroom/new... @danafarber.bsky.social @danafarbernews.bsky.social @harvardmed.bsky.social
July 28, 2025 at 11:22 AM
jia-luo.bsky.social
4/ In summary, if NUT carcinoma is suspected clinically – eg in a poorly differentiated aggressive cancer of lung, head or neck origin - clinicians should discuss with pathology colleagues whether a gold standard test for NUT carcinoma should be ordered

Our paper also includes co-mutations, fusions
July 28, 2025 at 11:22 AM
jia-luo.bsky.social
3/ Using our international registry (nc-registry.org), we found that while more DNA NGS panels are including NUT carcinoma defining fusion genes, this did not improve detection

Of note, NUT IHC (turnaround time ~7 days) is 100% specific in these cases

NUT IHC/FISH and RNA fusion are gold standards
Graph from paper showing NC detection pre vs post 2020. DNA panel tests included NUT carcinoma genes more, but fewer cases were identified in those who tested. RNA fusion testing is improving. A figure reminding that NUT IHC is 100% specific.
July 28, 2025 at 11:22 AM
jia-luo.bsky.social
1/ In Clinical Cancer Research, we examined underdiagnosis of NUT carcinoma, an aggressive squamous lung, head and neck cancer, and found >75% are missed on standard of care testing (DNA panel NGS)

🫁 🗣️ doi.org/10.1158/1078... #medsky #oncsky #meded #lcsm #lungcancer @theaacr.bsky.social

🧵A thread:
Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registry Abstract Purpose: NUT carcinoma (NC) is an underdiagnosed, poorly differentiated squamous cell cancer with a median survival of 6.7 months. Defined by NUTM1 fusions, NC enhances oncogene transcription, including MYC. We investigated the ability of standard next-generation sequencing (NGS) to identify NUTM1 fusions and describe additional molecular features of NC. Experimental Design: This study included 116 NC patients whose tumors underwent broad-panel NGS (>80 genes) of DNA, ctDNA, and/or RNA fusion sequencing between 2013-2024. NGS reports and medical records were manually reviewed. Results: Of 116 patients (median age 38, 40.5% female), 84.5% had DNA, 12.1% had ctDNA, and 51.7% had RNA fusion testing. In a subset of 100 patients with DNA/ctDNA testing, 92.9% (n=79/85) had <10 pack-years/never-smoking history, and 58.8% (n=47/80) had a BRD4::NUTM1 fusion. Median TMB was 1.0 mut/Mb (range 0.0-16.0; n=71 known), and 19.7% (n=13/66) had PD-L1 expression ≥1%. DNA, ctDNA, RNA fusion, NUT IHC, and NUTM1 FISH detected NC fusions in 21.6%, 21.4%, 83.9%, 100.0%, and 91.9% of tests, respectively. Co-occurring pathogenic mutations included oncogenes PIK3CA, RET, FGFR3, and tumor suppressors ATM and BRCA1 (n=1 each). Secondary genes altered in >5% of NCs included LRP1B (10.4%), MLL2/KMT2D (8.0%), and FAT1 (5.5%); common pathways with mutated genes were epigenetic (57.0%), cell cycle (26.0%), and DNA repair (24.0%). Conclusions: Standard DNA NGS detects less than a quarter of NUT carcinomas; RNA-based fusion testing, or NUT IHC/NUTM1 FISH, should be routine for suspected NC. NCs are enriched in co-occurring epigenetic, cell cycle, and DNA repair alterations, warranting further evaluation.
July 28, 2025 at 11:22 AM
jia-luo.bsky.social
🗺️ 🫁 Thrilled to work with and learn from this multi-D international panel of lung cancer experts

We’ve got a fantastic interactive discussion on pulmonary nodules planned - Tues Sept 9 @ IASLC #WCLC25 in Barcelona

Join us! / Register: wclc.iaslc.org

@iaslc.bsky.social #lcsm #medsky
Zoom picture of multidisciplinary panel of experts on lung cancers
July 16, 2025 at 2:11 PM
jia-luo.bsky.social
Celebrating a win - when a fantastic CRC in your group achieves their dream of going to medical school!
Coffee with mentees
July 9, 2025 at 2:52 PM
jia-luo.bsky.social
Great to meet friends and collaborators at #ASCO25

Look forward to discussing some of these practice changing results in treating lung cancers!
June 4, 2025 at 2:43 AM
jia-luo.bsky.social
🌟 Some great colleagues, including Dr Julia Rotow, and I will be discussing the latest practice changing data in oncology @ Best of ASCO Boston July 26-27!

Program and registration horizoncme.com/best-of-asco...

#oncsky @ascocancer.bsky.social @danafarbernews.bsky.social @danafarber.bsky.social
This two-day conference is an Official Annual Meeting Review of ASCO25, featuring expert faculty who will review findings, discuss potential impacts on the current standard of care, and apply the results within the clinical context of a patient case.
May 19, 2025 at 9:52 PM
jia-luo.bsky.social
🌟 Outstanding AACR Scientific Achievement Award lecture by Dr Alice Shaw on decades of research led by her and many others on developing effective targeted medicines for lung cancers

#AACR25 @theaacr.bsky.social @danafarber.bsky.social #lcsm
April 29, 2025 at 12:05 AM
jia-luo.bsky.social
Fantastic stories on the development to date of 3 rational targeted therapy combinations in KRAS driven lung cancers by Dr Alice Shaw at #AACR25

@danafarber.bsky.social @theaacr.bsky.social #lcsm
April 28, 2025 at 5:43 PM
jia-luo.bsky.social
Excellent comprehensive presentation by Dr Andy Aguirre on emerging mechanisms of resistance to RAS inhibitors and future promising combinations in pancreatic cancers

#AACR25 @theaacr.bsky.social @danafarber.bsky.social
April 28, 2025 at 4:36 PM
jia-luo.bsky.social
And great discussion by Dr Bivona on the history of RAS oncogene, preclinical studies, and future of developing effective medicines for KRAS G12D driven cancers!
April 27, 2025 at 10:54 PM
jia-luo.bsky.social
#AACR25 great presentation by Dr Arbour on initial safety and efficacy signal of KRAS G12D inhibitor zoldonrasib (RMC-9805) in NSCLC

#lcsm
April 27, 2025 at 10:47 PM
jia-luo.bsky.social
"Upholding Our Values, Defending Our University" www.harvard.edu/president/ne...
April 21, 2025 at 9:33 PM
jia-luo.bsky.social
Great to catch up with NUT carcinoma research collaborator and friend Dr Robert Hsu (USC)

What a champion - from clinic, to a red eye, to team @danafarber.bsky.social marathon monday! 🙌🏻

#lcsm #oncsky
Dinner with a champ and wonderful collaborator, Dr Robert Hsu. He is in town for the Boston marathon and running for team Dana-Farber!
April 20, 2025 at 10:35 PM
jia-luo.bsky.social
Celebrating Patty Brent with TOP colleagues Drs Matt Oser and Michael Rabin

Thank you, Patty, for all that you have done 🙏🏻

@danafarber.bsky.social @danafarbernews.bsky.social
April 17, 2025 at 10:32 PM
jia-luo.bsky.social
A season of celebration - huge congratulations to superstar mentees who will be moving on to new adventures, including UCLA med and Harvard med!! The future is bright!
April 4, 2025 at 9:47 AM
jia-luo.bsky.social
📚 Thank you Drs Prince, Chijioke, and Bubendorf for your Editorial on our work on "lung adenocarcinomas with mucinous features" in Ann of Oncology, highlighting the importance of better characterizing this NSCLC subtype & its translational implications

www.annalsofoncology.org/article/S092... #lcsm
Title page of "Unravelling lung adenocarcinoma with mucinous histology and its translational implications", Annals of Oncology Editorial
March 16, 2025 at 7:40 PM
jia-luo.bsky.social
Outstanding and inspiring talk by Dr Alice Shaw on 20+yr of multidisciplinary scientific collaborations to develop effective therapies for ALK+ lung cancers at the DFCI CCG Symposium

@danafarber.bsky.social #lcsm #oncsky
March 14, 2025 at 9:08 PM